Literature DB >> 16816953

Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedione.

M Emoto, N Fukuda, Y Nakamori, A Taguchi, S Okuya, Y Oka, Y Tanizawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16816953     DOI： 10.1007/s00125-006-0313-5

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  8 in total

1.  The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients.

Authors:  T Baba; K Shimada; S Neugebauer; D Yamada; S Hashimoto; T Watanabe
Journal:  Diabetes Care       Date:  2001-05       Impact factor: 19.112

2.  Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.

Authors:  YouFei Guan; Chuanming Hao; Dae Ryong Cha; Reena Rao; Wendell Lu; Donald E Kohan; Mark A Magnuson; Reyadh Redha; Yahua Zhang; Matthew D Breyer
Journal:  Nat Med       Date:  2005-07-10       Impact factor: 53.440

Review 3.  The syndrome of inappropriate secretion of antidiuretic hormone.

Authors:  F C Bartter; W B Schwartz
Journal:  Am J Med       Date:  1967-05       Impact factor: 4.965

4.  Pathophysiological consequences of VEGF-induced vascular permeability.

Authors:  Sara M Weis; David A Cheresh
Journal:  Nature       Date:  2005-09-22       Impact factor: 49.962

5.  The insulin sensitiser pioglitazone does not influence skin microcirculatory function in patients with type 2 diabetes treated with insulin.

Authors:  J E Tooke; L M Elston; K M Gooding; C I Ball; D M Mawson; J Piper; R Sriraman; R Urquhart; A C Shore
Journal:  Diabetologia       Date:  2006-03-01       Impact factor: 10.122

6.  Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes.

Authors:  I E Kelly; T S Han; K Walsh; M E Lean
Journal:  Diabetes Care       Date:  1999-02       Impact factor: 19.112

7.  Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes.

Authors:  M Emoto; T Anno; Y Sato; K Tanabe; S Okuya; Y Tanizawa; A Matsutani; Y Oka
Journal:  Diabetes       Date:  2001-05       Impact factor: 9.461

Review 8.  Considerations for management of fluid dynamic issues associated with thiazolidinediones.

Authors:  Norman K Hollenberg
Journal:  Am J Med       Date:  2003-12-08       Impact factor: 4.965
  8 in total
  3 in total

Review 1.  Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies.

Authors:  Janaka Karalliedde; Robin E Buckingham
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 2.  PPARgamma and its ligands: therapeutic implications in cardiovascular disease.

Authors:  Luis Villacorta; Francisco J Schopfer; Jifeng Zhang; Bruce A Freeman; Y Eugene Chen
Journal:  Clin Sci (Lond)       Date:  2009-02       Impact factor: 6.124

3.  Relationship between urinary sodium excretion and pioglitazone-induced edema.

Authors:  Akinobu Nakamura; Takeshi Osonoi; Yasuo Terauchi
Journal:  J Diabetes Investig       Date:  2010-10-19       Impact factor: 4.232
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.